Fluticasone propionate intranasal - OptiNose

Drug Profile

Fluticasone propionate intranasal - OptiNose

Alternative Names: FLU-EDS; OPN-375; Opt-FP; OPTINOSE; OptiNose fluticasone propionate

Latest Information Update: 04 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OptiNose AS
  • Developer OptiNose
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Nasal polyps
  • Phase III Sinusitis
  • Phase I Asthma

Most Recent Events

  • 03 Mar 2017 Pharmacokinetic data from phase I trials in healthy volunteers presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI - 2017)
  • 03 Mar 2017 Efficacy and adverse events data from a phase III trial in indication) presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAI-2017)
  • 31 Jan 2017 The US FDA sets PDUFA date of September 2017 for NDA review for Nasal polyps (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top